Citi Cuts Novo Nordisk Price Target to DKK 296 on Limited Margin Growth Outlook
Citi reduced its price target for Novo Nordisk (NVO) to DKK 296 from DKK 310, citing limited margin growth through 2030 despite strong sales of Wegovy. The bank maintained a 'neutral' rating, noting stable margins and higher R&D spending. Citi also cut its 2027-2030 EPS growth forecast to 9% from 12%, but raised near-term estimates due to Wegovy pill sales. Q3 revenue is expected to exceed consensus, but profit may align with expectations due to margin pressures.
How this was made
The 30-second read
Why it matters
Analyst downgrade may trigger short‑term price decline, but improved near‑term sales forecasts could moderate the move.
Market read
The new target cut provides fresh actionable insight for traders holding or considering Novo Nordisk.
What to watch
Citi's target cut may underweight the impact of expanding oral Wegovy sales and new market entries.
Background
Citi's research note follows Novo Nordisk's Capital Markets Day and precedes its upcoming Q3 earnings release.
Ticker impact
Citi lowered Novo Nordisk's price target to DKK 296, citing limited margin growth, marking a new analyst downgrade.
downward pressure as investors reassess valuation
The target reduction reflects concerns over margin expansion, a material change in analyst view that can move the stock.
Market effects
Potentially dampens sentiment for the broader pharma/obesity‑treatment sector.
May affect European biotech sentiment, especially Danish stocks.
Limited to Novo Nordisk and peers; no broad market shift expected.
Counterpoint
The near‑term sales uplift from the Wegovy pill could offset margin concerns, supporting a hold or buy.
Key entities
- companyNovo Nordisk
Danish pharmaceutical firm focused on obesity and diabetes treatments.
- analystCiti Research
Investment bank providing the price target revision.
